SNY
Sanofi American Depositary Shares (Each representing one-half of one ordinary share)
Company · XNAS · US · USD
Market price
$43.54
+$1.04 (+2.45%) · 3 months
| Date and time | Price |
|---|---|
| May 11, 2026 | $42.50 |
| May 12, 2026 | $42.86 |
| May 13, 2026 | $42.42 |
| May 14, 2026 | $42.85 |
| May 15, 2026 | $42.69 |
| May 18, 2026 | $43.54 |
| May 19, 2026 | $43.55 |
| May 20, 2026 | $44.67 |
| May 21, 2026 | $44.92 |
| May 22, 2026 | $44.29 |
| May 26, 2026 | $44.15 |
| May 27, 2026 | $44.43 |
| May 28, 2026 | $44.29 |
| May 29, 2026 | $43.67 |
| Jun 1, 2026 | $42.96 |
| Jun 2, 2026 | $42.80 |
| Jun 3, 2026 | $42.37 |
| Jun 4, 2026 | $44.38 |
| Jun 5, 2026 | $45.02 |
| Jun 8, 2026 | $43.88 |
| Jun 9, 2026 | $44.73 |
| Jun 10, 2026 | $43.57 |
| Jun 11, 2026 | $44.11 |
| Jun 12, 2026 | $44.25 |
| Jun 15, 2026 | $43.80 |
| Jun 16, 2026 | $44.05 |
| Jun 17, 2026 | $42.50 |
| Jun 18, 2026 | $42.38 |
| Jun 22, 2026 | $41.78 |
| Jun 23, 2026 | $41.60 |
| Jun 24, 2026 | $41.33 |
| Jun 25, 2026 | $41.80 |
| Jun 26, 2026 | $42.95 |
| Jun 29, 2026 | $43.43 |
| Jun 30, 2026 | $42.66 |
| Jul 1, 2026 | $41.63 |
| Jul 2, 2026 | $43.16 |
| Jul 6, 2026 | $42.61 |
| Jul 7, 2026 | $42.98 |
| Jul 8, 2026 | $42.78 |
| Jul 9, 2026 | $43.90 |
| Jul 10, 2026 | $43.50 |
| Jul 13, 2026 | $44.00 |
| Jul 14, 2026 | $43.18 |
| Jul 15, 2026 | $43.68 |
| Jul 16, 2026 | $44.21 |
| Jul 17, 2026 | $44.66 |
| Jul 20, 2026 | $43.98 |
| Jul 21, 2026 | $43.75 |
| Jul 22, 2026 | $43.79 |
| Jul 23, 2026 | $43.36 |
| Jul 24, 2026 | $43.35 |
| Jul 27, 2026 | $44.00 |
| Jul 28, 2026 | $45.54 |
| Jul 29, 2026 | $44.85 |
| Jul 30, 2026 | $42.89 |
| Jul 31, 2026 | $43.08 |
| Aug 3, 2026 | $42.95 |
| Aug 4, 2026 | $42.68 |
| Aug 5, 2026 | $42.78 |
| Aug 6, 2026 | $42.89 |
| Aug 7, 2026 | $43.46 |
| Aug 10, 2026 | $43.54 |
- Period change
- +2.45%
- Period low
- $41.33
- Period high
- $45.54
- Observations
- 63
- Updated
- Aug 10, 2026, 6:27 PM
About Sanofi American Depositary Shares (Each representing one-half of one ordinary share)
Sanofi develops and markets drugs with a concentration in immunology, vaccines, and rare diseases. Although the company offers a diverse array of drugs, its highest-revenue product, Dupixent, accounts for over 30% of total sales. Profits for this immunology blockbuster drug are shared with Regeneron. About 45% of total revenue comes from the United States, 20% from Europe, and 6% from China.
Company websiteClassifications
- Biotechnology · Biotech
- Pharmaceuticals · Pharma
- Healthcare
Market details
- Type
- Company
- Market
- XNAS
- Operating market
- XNAS
- Country
- US
- Currency
- USD
- Market capitalization
- $103,225,597,899.60
- Employees
- 74.8K